14.3 Panel Problem-Solving and Common Traps

14.3 Panel Problem-Solving and Common Traps

Quick Answer: Before you name an antibody, exclude the look-alikes: RhIG anti-D, HTLA, rouleaux (saline replacement), cold auto masking allo (prewarm or cold adsorption), drug antibodies, recent-transfusion mixed field, and a positive DAT that invalidates phenotyping. Neutralize Lewis, P1, Ch/Rg, and Sda. A DTT-treated cell panel destroys Kell, Lutheran, Dombrock, JMH (and some others); DTT-treated serum knocks out IgM. Screen pos / AC pos / panel all pos is warm auto versus high-prevalence versus multiple antibodies — DAT, history, and adsorption decide. Send unresolved high-prevalence, hidden allo, and rare-unit problems to the IRL.

The clean anti-Jka panel in Section 14.1 is the teaching case. The exam also writes the dirty ones. IV.A.3 expects you to name the trap and the next tube, not to force a single specificity onto a panagglutinin.

Passive anti-D is not immunization

A D-negative woman at 28 weeks or postpartum, or after a massive-FMH dose of RhIG, will have anti-D on the panel. It is passive, usually ≤1+ to 2+, titer often ≤4, AC negative, and the history dates the injection. Do not call her immunized, do not stop future RhIG, and do not hunt a second antibody so hard that you forget to finish non-D rule-outs — RhIG does not explain anti-K or anti-Jka. If the titer is high (classically ≥16) or the last RhIG was months ago, treat it as immune anti-D until proven otherwise.

HTLA versus a real alloantibody

High-titer, low-avidity (HTLA) antibodies (Knops, Ch/Rg, Yka, Csa) give weak (weak 1+ to 1+) reactions with most or all panel cells, little dosage, and a negative or weak AC. The giveaway is that the weak reaction survives dilution — a titer of 64 with a 1+ endpoint. They do not cause HTR. Anti-Ch and anti-Rg are neutralized by pooled plasma (soluble C4). Knops antibodies are weakened by DTT or enzymes. Do not spend a night of selected cells on a 1+ panagglutinin that titers to 128 and is neutralized by plasma — but do make sure a clinically significant antibody is not hiding underneath (PEG, selected cells, or adsorption). HTLA is a diagnosis of a named system after you have excluded Kidd, Duffy, Rh, Kell, and S/s, not a shrug that skips rule-out.

Rouleaux is not agglutination

Rouleaux (stacked-coin red cells) happens in paraprotein, Wharton's jelly, and some high-protein enhancement media. It appears at IS and 37 °C and disappears after washing, so the AHG phase is usually negative. True IgG agglutination survives wash and is read at AHG. Saline replacement: centrifuge the plasma-cell mix, remove plasma, replace with saline, resuspend. Rouleaux disperses; true agglutination does not. Do not “rule in anti-M” on an IS-only panel that clears with saline replacement, and do not call rouleaux a warm auto — the AC at AHG after washing should be 0.

Cold auto masking allo, drugs, mixed field, and a DAT that lies about the phenotype

Cold autoanti-I (or IH) reacts with all adult cells including the AC at IS/RT and can carry into 37 °C if you do not warm things properly. It can mask an IgG alloantibody. Fix: prewarm technique (cells, plasma, and saline at 37 °C, no IS read) or cold autologous adsorption, then run a strict 37 °C / AHG panel. Cord cells (i) are a clue, not a full workup. Do not prewarm so aggressively that you melt a Kidd antibody — prewarm is for cold panagglutination, not for a clean AHG screen you simply dislike.

Drug-dependent antibodies (piperacillin, cefotetan, penicillin) produce a positive DAT. The eluate may be nonreactive with untreated cells and reactive only in the presence of drug. Methyldopa / fludarabine-type autoantibodies behave like warm autos. Get a medication list before you call every panagglutinin idiopathic WAIHA.

Recent transfusion produces mixed-field antigen typing and can make the AC and DAT positive because alloantibody is coating donor cells (delayed serologic or hemolytic reaction). Phenotype is invalid. Use genotype or retic separation. The “panel” may be the patient's new alloantibody plus leftover donor cells in the AC.

A positive DAT invalidates antigen typing that uses AHG or high-protein reagents — the cells are already coated. Use monoclonal IgM direct agglutinins, or strip IgG with chloroquine diphosphate or EGA and repeat. Do not report a patient as e+ on an AHG anti-e when the DAT is 3+.

Neutralization and the DTT panel

Soluble substance neutralizes some antibodies so leftover reactivity can be identified:

If neutralization kills the reactions, that was the antibody. If reactions remain, something significant is underneath.

DTT-treated reagent cells lose antigens that depend on disulfide bonds: Kell, Lutheran, Dombrock, JMH, Yt, Knops, LW (weakened), and CD38 (daratumumab interference). Rh, Kidd, Duffy, and MNS survive. An unidentified AHG antibody that vanishes on DTT cells is in a DTT-sensitive system — most often Kell. DTT-treated plasma/serum disrupts IgM pentamers. Reactivity that disappears after treating the serum (not the cells) is IgM, not IgG anti-K. That is how you separate IgM noise from true IgG anti-K, and how you strip IgM so you can see IgG underneath.

Daratumumab (anti-CD38) makes a panagglutinin at AHG. DTT-treated panel cells (CD38 destroyed) let you rule out most alloantibodies, but Kell is also destroyed, so you cannot rule out anti-K on a DTT panel — issue K− units or use a non-DTT method for K.

Worked scenario: screen positive, autocontrol positive, panel all positive

A 68-year-old with anemia: screen 3+ all cells, AC 3+, 11-cell panel 3+ with every cell at AHG, IS negative.

This single picture has three exam diagnoses. You do not pick one from the panel alone.

1. Warm autoantibody. DAT IgG-positive, eluate panreactive, no recent transfusion. The panel is the auto. Next question: is there an underlying alloantibody? If not recently transfused → autologous adsorption, then panel the adsorbed plasma. If recently transfused → differential allogeneic adsorption. Do not just issue “least incompatible” without looking for alloanti-Jka underneath.

2. High-prevalence alloantibody with a coincidentally positive AC (or high-prevalence plus a warm auto). Clue: the patient types negative for a high-prevalence antigen (U, k, Kpb, Vel, Lub). The AC should be negative for a pure high-prevalence allo — if AC is truly 3+ with a negative DAT, suspect a technique problem. A negative AC with a panreactive panel is the cleaner high-prevalence postcard (Section 14.2).

3. Multiple alloantibodies covering every panel cell, plus a positive AC from recent transfusion. Clue: transfusion 10 days ago, falling hemoglobin, mixed-field DAT or phenotype, eluate reactive with some cells (the donor phenotype) rather than all. Selected cells and phenotype-matched adsorbing cells unravel the mixture.

Algorithm: history (transfusion, pregnancy, RhIG, daratumumab, antibiotics) → DAT IgG/C3 → eluate → phenotype or genotype → enzymes/DTT/neutralization as indicated → adsorption if auto → IRL if you still have a panagglutinin you cannot name or you need rare antigen-negative units.

When to send to the IRL

Send, do not guess:

• Suspected high-prevalence antibody or antibody to an unidentified specificity after selected cells.
• Warm auto in a recently transfused patient when you cannot complete differential adsorption.
• Need for rare units (Ko, U−, Vel−, PP1Pk−, Jk(a−b−)).
• HDFN with a rare maternal antibody.
• Discrepant neutralization / DTT / enzyme results.
• HTLA versus clinically significant that you cannot separate.

Ship plasma, EDTA cells, and a DAT/eluate if already done. Tell them the transfusion and drug history. The IRL is not a substitute for finishing the homozygous rule-outs you can do locally.

Exam traps

• Calling RhIG anti-D immune and withholding later RhIG.
• Antigen-negative units for a Knops antibody.
• Reading rouleaux at IS as anti-M and skipping saline replacement.
• Prewarming away a Kidd antibody because you were chasing a cold.
• Phenotyping through a 3+ DAT.
• Using a DTT cell panel to rule out anti-K in a daratumumab patient — DTT destroys K.
• Issuing least-incompatible blood for a panagglutinin without adsorption.